One in three antibiotic prescriptions in US unnecessary, says CDC
May 5, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDC, antibiotic, prescribing, prescriptions, unnecessary
Approximately 30% of all prescriptions of antibiotics in the United States are unnecessary, according to new data published by the …
Eli Lilly’s cancer drug candidate scores FDA priority review
May 5, 2016Eli Lilly, US FDA, oncology, regulation
US drugmaker Eli Lilly (NYSE: LLY) said the US Food and Drug Administration (FDA) has granted priority review for its …
Bayer’s liver cancer drug meets primary endpoint in late stage trial
May 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial
Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …
Biogen to spin off its haemophilia business
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Business, alprolix, eloctate, haemophilia, hemophilia, spin off, spin-off
Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …
Nice extends price-negotiation talks for PTC’ muscle wasting drug
May 4, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, market access, regulation
UK regulators have extended the cost negotiation talks with PTC Therapeutics (Nasdaq: PTCT) by a week for the drug to …
Pfizer revenue jumps 20%; ups FY16 outlook
May 4, 2016Research and Development, Sales and Marketing Pfizer, Q1, earnings, results, revenue, sales
US pharma giant Pfizer (NYSE: PFE) reported a 20% jump in first-quarter revenue boosted by performance of its new cancer …
Sun Pharma to partner with ICGEB to develop novel Dengue treatment
May 4, 2016Research and Development Dengue fever, Sun Pharma, collaboration, dengue, development, drug, icgeb, international centre for genetic engineering and biotechnology, partnership, sun pharmaceutical
Sun Pharmaceuticals (BSE: 85715) and the International Centre for Genetic Engineering and Biotechnology (ICGEB) are set to team up to …
US biotech company to try resurrect the clinically dead
May 4, 2016Research and Development US, bioquark, biotech, brain, central nervous system, clinically dead, dead, patients, ressurect
A US biotech firm has announced plans for a Phase I trial that will see them attempt to bring brain-dead …
Pfizer joins the race, bids for Medivation – Reports
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …
FDA grants priority review for Amgen leukaemia drug
May 4, 2016Research and Development, Sales and Marketing Amgen, FDA, blincyto, leukaemia, lymphoblastic leukaemia, paediatric
Amgen has announced that the US Food and Drug Administration (FDA) has granted priority review status for the supplemental Biologics …
Quintiles to merge with IMS Health
May 3, 2016Medical Communications, Research and Development, Sales and Marketing IMS Health, Quintiles, merger
IMS Health (NYSE: IMS) and Quintiles (NYSE: Q) have announced that a definitive merger agreement has been made between the …
New CFO at Mylan
May 3, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, cfo, kenneth parks
Mylan has announced the appointment of Kenneth S. Parks as its new chief financial officer, effective June 6 2016. Parks …
Google files for US patent to electronic eye lens
May 3, 2016Manufacturing and Production, Research and Development Alphabet, google, lens, patent, research
Alphabet Inc (Nasdaq: GOOG) has filed a patent application for a device that can be implanted in the eye to …
EMA recommends Biogen’s MS treatment Zinbryta
May 3, 2016Research and Development, Sales and Marketing Biogen, CHMP, EMA, daclizumab, zinbryta
The Committee for Medicinal Products for Human Use (CMHP) has recommended the granting of a marketing authorisation for Zinbryta (daclizumab) …
In-depth: MSF takes on Pfizer, GSK
May 3, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Doctors Without Borders, GSK, Pfizer, analysis, medicins sans frontieres, patents, pneumonia
Medicins Sans Frontieres (MSF) recently stepped up their campaign to make the pneumonia vaccine more available in developing countries. Appearing …
France to push for drug price control regulations at upcoming G7 summit
May 3, 2016Manufacturing and Production Drug pricing, France, drug prices, g7 summit, hollande, irreversible, medicines, pharmaceutical, prices
France will urge its fellow G7 partners to introduce strict and final new limits to control the prices of new …
Weekly Movers: Neuren Pharma, Eli Lilly, Gilead Sciences…
May 3, 2016Manufacturing and Production
Corporate result announcements remained the key focus as well as the primary drivers for stock movements this week as the …
Regeneron says trial drug for osteoarthritis pain meets primary endpoint in Phase II trials
May 3, 2016Manufacturing and Production, Research and Development Phase II, Regeneron Pharmaceuticals, drug trial, osteoarthritis, phase III
Regeneron Pharmaceuticals (Nasdaq: REGN) said mid-stage trials for its drug candidate to treat osteoarthritis pain med its primary endpoint. The …
Big investor hits back at critics as Valeant’s war of words gathers pace
May 3, 2016Manufacturing and Production, Sales and Marketing Valeant, ackman, allegations, buffett, practices, price gouging, price rises, scandal
Valeant have hit the mainstream news again after key investor Bill Ackman mounted a robust defence of the company, ruling …
Allergan launches Crestor generic in the US
May 3, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales
Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
